Edition:
India

Avadel Pharmaceuticals PLC (AVDL.OQ)

AVDL.OQ on NASDAQ Stock Exchange Global Market

1.35USD
9:08pm IST
Change (% chg)

$0.03 (+2.27%)
Prev Close
$1.32
Open
$1.31
Day's High
$1.35
Day's Low
$1.31
Volume
7,357
Avg. Vol
34,380
52-wk High
$7.96
52-wk Low
$1.03

Latest Key Developments (Source: Significant Developments)

Avadel Pharmaceuticals Q1 Loss Per Share $0.35
Wednesday, 8 May 2019 

Avadel Pharmaceuticals PLC ::AVADEL PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.35.Q1 REVENUE $16.4 MILLION VERSUS $33.3 MILLION.REVENUES FOR Q1 OF 2019 WERE $16.4 MILLION, COMPARED TO $33.3 MILLION IN Q1 OF 2018.HOSPITAL PRODUCT REVENUE FOR 2019 IS NOW EXPECTED TO EXCEED $30 MILLION.AVADEL PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $79.9 MILLION AS OF MARCH 31, COMPARED TO $99.9 MILLION AS OF DECEMBER 31, 2018.  Full Article

Avadel Pharmaceuticals says Michael S. Anderson Resigned As CEO
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Avadel Pharmaceuticals PLC ::AVADEL PHARMACEUTICALS ANNOUNCES CHANGES TO MANAGEMENT TEAM AND BOARD OF DIRECTORS.MICHAEL S. ANDERSON RESIGNS AS CHIEF EXECUTIVE OFFICER AND MEMBER OF AVADEL'S BOARD OF DIRECTORS.GREGORY J. DIVIS, CURRENT AVADEL CHIEF OPERATING OFFICER, NAMED INTERIM CHIEF EXECUTIVE OFFICER.GEOFFREY M. GLASS, CURRENT MEMBER OF AVADEL'S BOARD OF DIRECTORS, NAMED CHAIRMAN.  Full Article

Avadel Pharmaceuticals Reports Q3 Adjusted Loss Per Share Of $0.65
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Avadel Pharmaceuticals PLC ::AVADEL PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 REVENUE $19.8 MILLION VERSUS I/B/E/S VIEW $23.3 MILLION.SEES FY 2018 REVENUE $90 MILLION TO $105 MILLION.QUARTERLY GAAP LOSS PER SHARE $0.43.QUARTERLY ADJUSTED LOSS PER SHARE $0.65.  Full Article

Avadel Pharmaceuticals Reports Q4 Adjusted Loss Per Share $0.28
Thursday, 8 Mar 2018 

March 8 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS.Q4 ADJUSTED LOSS PER SHARE $0.28.Q4 GAAP LOSS PER SHARE $0.24.Q4 REVENUE $34.2 MILLION VERSUS $43.1 MILLION.SEES FY 2018 REVENUE $105 MILLION TO $125 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.31, REVENUE VIEW $34.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Avadel Pharmaceuticals Announces Proposed Exchangeable Senior Notes Offering
Wednesday, 14 Feb 2018 

Feb 13 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS ANNOUNCES PROPOSED EXCHANGEABLE SENIOR NOTES OFFERING.AVADEL PHARMACEUTICALS PLC - UNIT INTENDS TO OFFER $125 MILLION PRINCIPAL AMOUNT OF EXCHANGEABLE SENIOR NOTES DUE 2023 IN A PRIVATE OFFERING​.  Full Article

Avadel Pharma Receives Orphan Drug Designation From FDA For FT 218
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR FT 218 FOR THE TREATMENT OF NARCOLEPSY.  Full Article

Avadel Pharmaceuticals Issues 2018 Corporate Outlook
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Avadel Pharmaceuticals Plc ::AVADEL PHARMACEUTICALS ISSUES 2018 CORPORATE OUTLOOK.REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE VIEW $0.25 TO $0.35.SEES FY 2018 REVENUE $110 MILLION TO $130 MILLION.SEES FY 2017 REVENUE $165 MILLION TO $175 MILLION.- ‍NDA FILING FOR FT218 EXPECTED BY YEAR-END 2018​.- COMMERCIAL LAUNCH FOR NOCTIVA ON TARGET FOR Q2 2018.FY2017 EARNINGS PER SHARE VIEW $1.48, REVENUE VIEW $171.8 MILLION -- THOMSON REUTERS I/B/E/S.AVADEL PHARMACEUTICALS- AV001 IS EXPECTED TO COMPETE IN AN ESTIMATED MARKET SIZE OF ABOUT $30 - $40 MILLION PER YEAR ONCE LAUNCHED IN 2019.- EXPECTS NEGATIVE CASH FLOW IN 2018.- ‍ASSESSING TAX CUTS AND JOBS ACT OF 2017 AND, ACCORDINGLY, IS UNABLE TO PROVIDE 2018 ADJUSTED DILUTED EPS GUIDANCE​.AVADEL PHARMACEUTICALS - ESTIMATES THAT PEAK REVENUES FOR NOCTIVA COULD BE AS HIGH AS $750 MILLION OR MORE PER YEAR.  Full Article

Avadel Pharmaceuticals Plc says Avadel licensee and Serenity amended exclusivity agreement on Sept 1
Wednesday, 6 Sep 2017 

Sept 5 (Reuters) - Avadel Pharmaceuticals Plc :Avadel Pharmaceuticals Plc says on September 1, 2017, Avadel licensee and Serenity amended exclusivity agreement.Avadel Pharma-under amendment $5 million deposited into escrow by Avadel licensee will continue to be held & will deposit additional $47 million - SEC filing.  Full Article

Avadel Pharmaceuticals Plc ‍enters into a license agreement with Serenity Pharmaceuticals Llc​
Wednesday, 6 Sep 2017 

Sept 5 (Reuters) - Avadel Pharmaceuticals Plc :Avadel Pharmaceuticals Plc - ‍entered into a license agreement with Serenity Pharmaceuticals Llc​.Avadel Pharmaceuticals Plc - ‍deal includes $50 million upfront payment; funded by cash on hand​.Avadel - ‍terms of agreement also include $20 million due at earlier of full scale commercial launch or June 30, 2018, performance-based milestones​.  Full Article

Avadel Pharmac enters into negotiations with Serenity Pharma for Noctiva
Friday, 18 Aug 2017 

Aug 17 (Reuters) - Avadel Pharmaceuticals Plc :Avadel Pharmaceuticals enters into exclusive negotiations with Serenity Pharmaceuticals for Noctiva™.Avadel Pharmaceuticals Plc - ‍entered into an agreement for right to exclusively negotiate with Serenity Pharmaceuticals, Llc.Avadel Pharmaceuticals Plc - ‍agreement with serenity for sole rights to commercialize and further develop Noctiva in united states and canada​.Avadel Pharmaceuticals Plc - ‍exclusive negotiation period is expected to close on or before September 7, 2017​.Avadel Pharmaceuticals Plc - ‍if Avadel terminates negotiations without cause, Avadel must pay $10 million to Serenity​.Avadel Pharmaceuticals Plc - ‍if serenity terminates negotiations without cause, Serenity must pay $10 million to Avadel​.  Full Article